Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands

被引：11

作者：

Henry, Thea L. ^{[1
]}

De Brouwer, Bonnie F. E. ^{[2
]}

Van Keep, Marjolijn M. L. ^{[3
]}

Blankestijn, Peter J. ^{[4
]}

Bots, Michiel L. ^{[5
]}

Koffijberg, Hendrik ^{[5
]}

机构：

[1] Bresmed Hlth Solut, Sheffield S1 2DW, S Yorkshire, England

[2] Medtron Trading NL BV, Heerlen, Netherlands

[3] BresMed Hlth Solut, Utrecht, Netherlands

[4] Univ Med Ctr Utrecht, Dept Nephrol, Utrecht, Netherlands

[5] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands

来源：

JOURNAL OF MEDICAL ECONOMICS | 2015年 / 18卷 / 01期

关键词：

Cardiovascular disease; Cost-effectiveness; Prevention; Renal sympathetic denervation; Resistant hypertension;

D O I：

10.3111/13696998.2014.978453

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

Objectives: Safety and efficacy data for catheter-based renal denervation (RDN) in the treatment of resistant hypertension have been used to estimate the cost-effectiveness of this approach. However, there are no Dutch-specific analyses. This study examined the cost-effectiveness of RDN from the perspective of the healthcare payer in The Netherlands. Methods: A previously constructed Markov state-transition model was adapted and updated with costs and utilities relevant to the Dutch setting. The cost-effectiveness of RDN was compared with standard of care (SoC) for patients with resistant hypertension. The efficacy of RDN treatment was modeled as a reduction in the risk of cardiovascular events associated with a lower systolic blood pressure (SBP). Results: Treatment with RDN compared to SoC gave an incremental quality-adjusted life year (QALY) gain of 0.89 at an additional cost of (sic)1315 over a patient's lifetime, resulting in a base case incremental cost-effectiveness ratio (ICER) of (sic)1474. Deterministic and probabilistic sensitivity analyses (PSA) showed that treatment with RDN therapy was cost-effective at conventional willingness-to-pay thresholds ((sic)10,000-80,000/QALY). Conclusion: RDN is a cost-effective intervention for patients with resistant hypertension in The Netherlands.

引用

页码：76 / 87

页数：12

共 60 条

[1]

He J., Whelton P.K., Epidemiology and prevention of hypertension, Med Clin North Am, 81, pp. 1077-1097, (1997)

[2]

Whelton P.K., Epidemiology of hypertension, Lancet, 344, pp. 101-106, (1994)

[3]

Kearney P.M., Whelton M., Reynolds K., Et al., Global burden of hypertension: Analysis of worldwide data, Lancet, 365, pp. 217-223, (2005)

[4]

Ezzati M., Lopez A.D., Rodgers A., Et al., Selected major risk factors and global and regional burden of disease, Lancet, 360, pp. 1347-1360, (2002)

[5]

Sarafidis P.A., Bakris G.L., Resistant hypertension an overview of evaluation and treatment, J Am Coll Cardiol, 52, pp. 1749-1757, (2008)

[6]

Perkovic V., Huxley R., Wu Y., Et al., The burden of blood pressurerelated disease: A neglected priority for global health, Hypertension, 50, pp. 991-997, (2007)

[7]

Lawes C.M., Vander Hoorn S., Rodgers A., Et al., Global burden of bloodpressure- related disease, 2001, Lancet, 371, pp. 1513-1518, (2008)

[8]

Carrington M.J., Jennings G.L., Stewart S., Pattern of blood pressure in Australian adults: Results from a national blood pressure screening day of 13,825 adults, Int J Cardiol, 145, pp. 461-467, (2010)

[9]

Pimenta E., Calhoun D.A., Resistant hypertension: Incidence, prevalence, and prognosis, Circulation, 125, pp. 1594-1596, (2012)

[10]

Daugherty S.L., Powers J.D., Magid D.J., Et al., Incidence and prognosis of resistant hypertension in hypertensive patients, Circulation, 125, pp. 1635-1642, (2012)

← 1 2 3 4 5 6 →